- Since 2004 with Bellevue Asset Management as head biotech, lead portfolio manager of the BB Biotech (Lux) Fund and head BB Biotech Ltd
- 2001 - 2004 equity4life Asset Management Ltd, investment manager
- 2000 - 2001 UBS Warburg, equity analyst
- Master's degree in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
- PhD in Biotechnology of the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich
- Since 2004 with Bellevue Asset Management as senior biotech analyst and Head Bellevue Research Inc
- 1999 - 2004 Adams, Harkness & Hill, biotech equity analyst
- 1991 - 1999 SG Cowen, biotech equity analyst
- MBA, Suffolk University, Boston
- BA in Communications, Boston College
- Since 2006 with Bellevue Asset Management as analyst/portfolio manager biotech
- 2004-2006 Standford Group Company, senior vice president, equity analyst
- 2003-2004 Sterling Financial Investment Group, equity analyst
- 2002-2003 Adams, Harkness & Hil, vice president, equity analyst
- MBA, Texas Christian University
- BA in Microbiology and Zoology, Louisiana State University
- Since February 2011 with Bellevue Asset Management as portfolio manager BB Biotech (Lux) Fund and BB Biotech Ltd
- 2005 - 2011 UBS Global Asset Management, first as financial analyst and then as fund manager Healthcare
- 2003 - 2005 Postdoctoral fellow at the University Hospital Zurich
- Studies in biotechnology at the Swiss Federal Institute of Technology (ETH) Zurich
- PhD / doctorate in Immunology at the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich
- Since 2008 with Bellevue Asset Management as lead portfolio manager of the BB Medtech (Lux) Fund
- 2004 - 2008 Sonova, head investor relations
- 2000 - 2004 Obtree Technologies Inc., finance and investor relations
- 1996 - 2000 Bank Sarasin, medtech analyst
- Master’s degree in Business Economics, University of St. Gallen (HSG), CEFA charterholder
- Since 2008 with Bellevue Asset Management as portfolio manager of the BB Medtech (Lux) Fund
- 2004 - 2008 Deloitte & Touche LLP, business consultant with focus on the medtech and pharmaceutical sectors
- Master’s degree in Business Economics, University of St. Gallen (HSG)
- Since 2008 with Bellevue Asset Management as team head and portfolio manager of the BB Alpha Health Fund
- 2007 - 2008 GVO Asset Management, portfolio manager of a global long/short equity fund
- 2004 - 2006 Silvergate Capital Management, co-founder and responsible manager for the medtech portfolio
- 2001 - 2004 Invesco, equity analyst for USD 3 bn. flagship Invesco Health Sciences Fund
- MBA, University of Oxford
- BA in Business Economics and finance, Montana State University, USA
- Since 2008 with Bellevue Asset Management as biotech and pharma analyst, co-manager of BB Alpha Health Fund
- 2007 - 2008 EJF Capital, senior biotech analyst
- 2005 - 2007 Spectra Investment Group, biotech analyst
- 2003 - 2005 Rock Capital Partners, analyst
- BA in Neuroscience and Behavior, Wesleyan University, USA
- Since 2004 with Bellevue Asset Management as Head and senior investment advisor Venture Capital
- 2002 - 2004 Global Life Science Ventures, investment manager venture capital
- 1994 - 2002 McKinsey & Co. Zurich and New York, associate partner, consulting for international pharmaceutical companies
- 1992 - 1994 University Hospital of Basel, resident physician
- various board assignments with medtech and biotech companies
- MD from the University of Basel
- MBA, INSEAD Fontainebleau, France
- Since 2004 with Bellevue Asset Management as a senior investment advisor biotech ventures
- Various board assignments with biotech companies in Switzerland and the US
- 1999 - 2004 NMT and HBM BioVentures/BioMedinvest, investment manager venture capital
- 1998 - 1999 Sanofi-Synthélabo, strategic marketing
- PhD in Protein Chemistry, Swiss Federal Institute of Technology (ETH) Zurich
- MSc in Biochemistry and a Master's degree in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH) Zurich
- Studies at the Eberhard Karls Universitity of Tubingen, Germany
- Since 2004 with Bellevue Asset Management as senior investment advisor venture capital
- 2001 - 2004 Global Life Science Ventures, investment manager venture capital
- 2000 - 2001 Booz Allen & Hamilton, management consultant
- 1995 - 2000 Scientific research at the Swiss Federal Institute of Technology (ETH) Zurich and at the Center of Molecular Biology of University of Heidelberg / ZMBH, Germany
- PhD degree in Molecular Biology, University of Heidelberg
- Master's degree in Chemistry, University of North Carolina, USA
- 1995 - present Asset Management BAB N.V., Curaçao, Managing Director / Portfolio Management
- 1990 - 1995 CITCO Account Manager Securities Administration
- 1985 - 1989 Multilift, Head Administration
- 1984 - 1985 Higher Economic Education (HEAO)
- 2001 - present BB Biotech subsidiary, Curaçao, Chairman
- 2000 - 2001 CITCO, Managing Director
- 1992 - 2000 Ernst & Young, Netherlands and the Netherlands Antilles
- 1984 - 1992 Tax law, University of Leiden, the Netherlands
- 2007 - present Asset Management BAB N.V., Curaçao, Portfolio Management
- 2006 - 2007 NMT Services N.V., Account Manager / Securities Administrator
- 1997 - 2006 Decro Trust N.V., Securities Administration for large Dutch investment compan
- 1992 - 1996 CITCO, Securities Administration
- 2004 - 2005 Modern business administration
